H.C. Wainwright raised the firm’s price target on Oncolytics (ONCY) to $10 from $5 and keeps a Buy rating on the shares. The firm says the company’s “compelling” data in gastrointestinal tumors increase its confidence ahead of the FDA meeting. H.C. Wainwright is increasingly confident that pelareorep is advancing toward “actionable regulatory pathways” across three “high-value” cancer indications.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics Biotech Reports Increased Q3 Loss Amid Rising Expenses
- Is ONCY a Buy, Before Earnings?
- Oncolytics Biotech Forms Advisory Board to Advance GI Cancer Treatment
- Promising Potential of Oncolytics Biotech’s Pelareorep in SCAC: Buy Rating with $5 Price Target
- Oncolytics Biotech Reports Promising Anal Cancer Data with Pelareorep